PE20211811A1 - Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 - Google Patents
Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1Info
- Publication number
- PE20211811A1 PE20211811A1 PE2021000082A PE2021000082A PE20211811A1 PE 20211811 A1 PE20211811 A1 PE 20211811A1 PE 2021000082 A PE2021000082 A PE 2021000082A PE 2021000082 A PE2021000082 A PE 2021000082A PE 20211811 A1 PE20211811 A1 PE 20211811A1
- Authority
- PE
- Peru
- Prior art keywords
- compounds
- sulfonimidamide
- interleukin
- inhibitors
- activity
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 102000000589 Interleukin-1 Human genes 0.000 title 1
- 108010002352 Interleukin-1 Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 abstract 2
- UWTNYMLSOQNSQQ-FHEMDEPNSA-N 1-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)-3-[[(6S)-6-methoxy-6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-yl]sulfonimidoyl]urea Chemical compound C1CCC2=C(C=3CCCC=3C=C12)NC(=O)NS(=O)(=N)C=1C=NN2C=1OC[C@H](C2)OC UWTNYMLSOQNSQQ-FHEMDEPNSA-N 0.000 abstract 1
- MUOSAMPMSKMOMV-UHFFFAOYSA-N 1-(6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazin-3-ylsulfonimidoyl)-3-(1,2,3,5,6,7-hexahydro-s-indacen-4-yl)urea Chemical compound C1=2CCCC=2C=C2C(=C1NC(=O)N=S(=O)(N)C1=C3N(N=C1)CCCO3)CCC2 MUOSAMPMSKMOMV-UHFFFAOYSA-N 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 206010009887 colitis Diseases 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/424—Oxazoles condensed with heterocyclic ring systems, e.g. clavulanic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
- C07D231/24—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms having sulfone or sulfonic acid radicals in the molecule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862701313P | 2018-07-20 | 2018-07-20 | |
| PCT/US2019/042711 WO2020018975A1 (en) | 2018-07-20 | 2019-07-19 | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20211811A1 true PE20211811A1 (es) | 2021-09-14 |
Family
ID=67659954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021000082A PE20211811A1 (es) | 2018-07-20 | 2019-07-19 | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US12234245B2 (https=) |
| EP (1) | EP3823974A1 (https=) |
| JP (1) | JP7320595B2 (https=) |
| KR (1) | KR20210034596A (https=) |
| CN (1) | CN112513048A (https=) |
| AR (1) | AR115822A1 (https=) |
| AU (1) | AU2019306658A1 (https=) |
| BR (1) | BR112021001044A2 (https=) |
| CA (1) | CA3105521A1 (https=) |
| CL (1) | CL2021000153A1 (https=) |
| CO (1) | CO2021001530A2 (https=) |
| CR (1) | CR20210022A (https=) |
| IL (1) | IL279256A (https=) |
| MA (1) | MA53172A (https=) |
| MX (1) | MX2021000780A (https=) |
| PE (1) | PE20211811A1 (https=) |
| PH (1) | PH12021500005A1 (https=) |
| SG (1) | SG11202013062VA (https=) |
| TW (1) | TWI825134B (https=) |
| UA (1) | UA128558C2 (https=) |
| WO (1) | WO2020018975A1 (https=) |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| CR20210024A (es) | 2018-07-20 | 2021-02-22 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
| ES3042546T3 (en) * | 2018-11-13 | 2025-11-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3880673B1 (en) | 2018-11-13 | 2024-01-03 | Novartis AG | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020102576A1 (en) * | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3914585A1 (en) * | 2019-01-23 | 2021-12-01 | Novartis AG | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| WO2021002887A1 (en) * | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| KR20220064364A (ko) | 2019-07-17 | 2022-05-18 | 조마젠 바이오사이언시즈 엘티디 | 다발성 경화증(ms)의 치료를 위한 nlpr3 조절제로서의 n-((1,2,3,5,6,7-헥사하이드로-s-인다센-4-일)카바모일)-4,5,6,7-테트라하이드로벤조푸란-2-설폰아미드 유도체 및 관련 화합물 |
| EP3999179A1 (en) | 2019-07-17 | 2022-05-25 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| JP7392169B2 (ja) * | 2019-11-12 | 2023-12-05 | 成都百裕制薬股▲ふん▼有限公司 | アミド誘導体及びその調製方法並びに医薬における応用 |
| PH12022551767A1 (en) * | 2020-01-22 | 2023-11-29 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| PH12022552447A1 (en) * | 2020-03-16 | 2024-01-03 | Zomagen Biosciences Ltd | Nlrp3 modulators |
| AU2021257619A1 (en) | 2020-04-15 | 2022-12-15 | Janssen Pharmaceutica Nv | Pyrazolo[1,5-d][1,2,4]triazine-5(4H)-acetamides as inhibitors of the NLRP3 inflammasome pathway |
| CN115485026A (zh) | 2020-04-15 | 2022-12-16 | 詹森药业有限公司 | Nlrp3炎体途径抑制剂吡唑并[1，2-d][1，2，4]三嗪-2-基-乙酰胺 |
| EP4139312A1 (en) | 2020-04-23 | 2023-03-01 | JANSSEN Pharmaceutica NV | Tricyclic compounds as inhibitors of nlrp3 |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| US20230202989A1 (en) | 2020-05-28 | 2023-06-29 | Janssen Pharmaceutica Nv | Compounds |
| AU2021291065B2 (en) | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| CN116194445A (zh) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
| EP3974415A1 (en) | 2020-09-24 | 2022-03-30 | Janssen Pharmaceutica NV | Nlrp3 modulators |
| CN114539256B (zh) * | 2020-11-20 | 2024-02-02 | 上海拓界生物医药科技有限公司 | 三环化合物及其医药用途 |
| JP2024508017A (ja) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３を調節する４－アルコキシ－６－オキソ－ピリダジン誘導体 |
| CN116964052A (zh) | 2021-03-04 | 2023-10-27 | 詹森药业有限公司 | 调节nlrp3的4-氨基-6-氧代-哒嗪衍生物 |
| AU2022263621A1 (en) | 2021-04-29 | 2023-12-14 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282A (zh) * | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| CN116635373A (zh) * | 2021-05-10 | 2023-08-22 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| KR20240029027A (ko) | 2021-07-01 | 2024-03-05 | 얀센 파마슈티카 엔브이 | 5-옥소-피리도[2,3-d]피리다진-6(5H)-일 아세트아미드 |
| MX2024000634A (es) * | 2021-07-19 | 2024-02-13 | Genentech Inc | Compuestos de sulfonimidamida y usos de los mismos. |
| CN115894478B (zh) * | 2021-09-30 | 2025-04-04 | 杭州民生药物研究院有限公司 | 一种新型吡啶并吡唑类杂环化合物及其应用 |
| CN118541366A (zh) | 2021-12-22 | 2024-08-23 | Ac免疫有限公司 | 二氢噁唑衍生物化合物 |
| CN116804018A (zh) * | 2022-03-25 | 2023-09-26 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| CN117247393A (zh) * | 2022-06-17 | 2023-12-19 | 成都百裕制药股份有限公司 | 酰胺衍生物及其制备方法和在医药上的应用 |
| WO2024010772A1 (en) * | 2022-07-06 | 2024-01-11 | Kodiak Sciences Inc. | Nlrp3 inhibitors |
| EP4554945A1 (en) | 2022-07-14 | 2025-05-21 | AC Immune SA | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| AU2023313032A1 (en) | 2022-07-28 | 2025-01-23 | Ac Immune Sa | Novel compounds |
| GEAP202516743A (en) | 2022-09-23 | 2025-08-11 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
| AU2024280075A1 (en) | 2023-06-02 | 2025-12-11 | Merck Sharp & Dohme Llc | 5,6-Unsaturated Bicyclic Heterocycles Useful as Inhibitors of Nod-Like Receptor Protein 3 |
| WO2025101716A1 (en) * | 2023-11-07 | 2025-05-15 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Processes for synthesis of trifunctionalized sulfur(vi) compounds |
| US20250223290A1 (en) | 2023-12-14 | 2025-07-10 | Merck Sharp & Dohme Llc | Azaindazole derivatives useful as inhibitors of nod-like receptor protein 3 |
| AR134646A1 (es) | 2023-12-14 | 2026-02-04 | Merck Sharp & Dohme Llc | Derivados de indazol útiles como inhibidores de la proteína 3 del receptor similar a nod |
| WO2025133307A1 (en) | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Heterocyclic modulators of the nlrp3 inflammasome pathway |
| WO2025153532A1 (en) | 2024-01-16 | 2025-07-24 | NodThera Limited | Nlrp3 inhibitors and glp-1 agonists combination therapies |
| WO2025153624A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025153625A1 (en) | 2024-01-17 | 2025-07-24 | Ac Immune Sa | Imidazo[1,2-d][1,2,4]triazine derivatives for use as inhibitors of the nlrp3 inflammasome pathway |
| WO2025163069A1 (en) | 2024-01-31 | 2025-08-07 | Ac Immune Sa | Novel compounds |
| WO2025222076A1 (en) | 2024-04-19 | 2025-10-23 | Kyorin Pharmaceutical Co., Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as mrgprx2 antagonists for the treatment of inflammatory diseases |
| CN119100956B (zh) * | 2024-09-03 | 2025-12-02 | 大连理工大学 | 一种无催化剂的光驱动合成亚磺酰胺类化合物的方法 |
| WO2026057747A1 (en) | 2024-09-11 | 2026-03-19 | Ac Immune Sa | Therapeutic use of nlrp3 inflammasome pathway inhibitor compounds |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4705555A (en) * | 1984-08-08 | 1987-11-10 | E. I. Du Pont De Nemours And Company | Herbicidal triazines |
| US5216026A (en) | 1990-07-17 | 1993-06-01 | Eli Lilly And Company | Antitumor compositions and methods of treatment |
| DE19540995A1 (de) | 1995-11-03 | 1997-05-07 | Hoechst Ag | Substituierte Sulfonimidamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| PT1270565E (pt) | 1997-01-29 | 2004-09-30 | Pfizer | Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia |
| EP1214087A1 (en) | 1999-09-14 | 2002-06-19 | Pfizer Products Inc. | Combination treatment with il-1ra and compounds that inhibit il-1 processing and release |
| JP2005510542A (ja) | 2001-11-30 | 2005-04-21 | ファイザー・プロダクツ・インク | 炎症の治療のための、ｉｌ−１／１８阻害剤及びｔｎｆ阻害剤の組み合わせ。 |
| ES2600355T3 (es) | 2010-02-22 | 2017-02-08 | Raqualia Pharma Inc. | Uso de un antagonista del receptor EP4 en el tratamiento de dermatitis de contacto alérgica y psoriasis |
| US20140221340A1 (en) | 2011-09-02 | 2014-08-07 | Kyowa Hakko Kirin Co., Ltd. | Chemokine receptor activity regulator |
| CA2913154A1 (en) | 2013-05-21 | 2014-11-27 | Virginia Commonwealth University | Cryopyrin inhibitors for preventing and treating inflammation |
| SI3259253T1 (sl) * | 2015-02-16 | 2020-07-31 | The University Of Queensland | Sulfonilsečnine in sorodne spojine ter njihova uporaba |
| FR3046933B1 (fr) | 2016-01-25 | 2018-03-02 | Galderma Research & Development | Inhibiteurs nlrp3 pour le traitement des pathologies cutanees inflammatoires |
| JP2019512009A (ja) | 2016-02-16 | 2019-05-09 | ザ・ユニバーシティ・オブ・クイーンズランド | スルホニルウレアおよび関連化合物ならびにこれらの利用 |
| US11447460B2 (en) | 2016-04-18 | 2022-09-20 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| US11339136B2 (en) | 2016-04-18 | 2022-05-24 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| EP3571187B1 (en) | 2017-01-23 | 2023-11-22 | Genentech, Inc. | Chemical compounds as inhibitors of interleukin-1 activity |
| JP7072586B2 (ja) | 2017-05-24 | 2022-05-20 | ザ ユニバーシティ オブ クィーンズランド | 新規な化合物及び使用 |
| WO2018225018A1 (en) * | 2017-06-09 | 2018-12-13 | Cadila Healthcare Limited | Novel substituted sulfoximine compounds |
| EP3649112A1 (en) | 2017-07-07 | 2020-05-13 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| NZ760129A (en) | 2017-07-07 | 2025-12-19 | Inflazome Ltd | Novel sulfonamide carboxamide compounds |
| ES2988798T3 (es) | 2017-07-24 | 2024-11-21 | Novartis Ag | Compuestos y composiciones para el tratamiento de afecciones asociadas a la actividad de NLRP |
| EP3668601A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| US20210122739A1 (en) | 2017-08-15 | 2021-04-29 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| EP3668843A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| JP2020531435A (ja) | 2017-08-15 | 2020-11-05 | インフレイゾーム リミテッド | 新規なスルホンアミドカルボキサミド化合物 |
| UY37848A (es) | 2017-08-15 | 2019-03-29 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3 |
| EP3668840A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| MA49903A (fr) | 2017-08-15 | 2020-06-24 | Inflazome Ltd | Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3 |
| WO2019043610A1 (en) | 2017-08-31 | 2019-03-07 | Cadila Healthcare Limited | NEW SUBSTITUTED SULFONYLUREA DERIVATIVES |
| EP3692020A1 (en) | 2017-10-03 | 2020-08-12 | Inflazome Limited | Novel compounds |
| WO2019092172A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| CN111315733A (zh) | 2017-11-09 | 2020-06-19 | 英夫拉索姆有限公司 | 新颖磺酰胺甲酰胺化合物 |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| US11905252B2 (en) | 2018-03-02 | 2024-02-20 | Inflazome Limited | Compounds |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201803394D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| GB201806578D0 (en) | 2018-04-23 | 2018-06-06 | Inflazome Ltd | Novel compound |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| AU2019299444A1 (en) | 2018-07-03 | 2021-01-14 | Novartis Ag | Methods of treating or selecting a treatment for a subject resistant to tnf inhibitor using a NLRP3 antagonist |
| CR20210024A (es) | 2018-07-20 | 2021-02-22 | Hoffmann La Roche | Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1 |
| TWI811400B (zh) | 2018-07-20 | 2023-08-11 | 德商歌林達有限公司 | 經進一步取代之三唑并喹噁啉衍生物 |
| CA3105521A1 (en) | 2018-07-20 | 2020-01-23 | F. Hoffmann-La Roche Ag | Sulfonimidamide compounds as inhibitors of interleukin-1 activity |
| KR20210053910A (ko) | 2018-08-15 | 2021-05-12 | 인플라좀 리미티드 | 신규한 설폰아마이드유레아 화합물 |
| GB201902327D0 (en) | 2019-02-20 | 2019-04-03 | Inflazome Ltd | Novel compounds |
| GB201817038D0 (en) | 2018-10-19 | 2018-12-05 | Inflazome Ltd | Novel processes |
| JP2022505525A (ja) | 2018-10-24 | 2022-01-14 | ノバルティス アーゲー | Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物 |
| US12134611B2 (en) | 2018-11-13 | 2024-11-05 | Novartis Ag | Compounds and compositions for treating conditions associated with NLRP activity |
| ES3042546T3 (en) | 2018-11-13 | 2025-11-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| WO2020102576A1 (en) | 2018-11-16 | 2020-05-22 | Novartis Inflammasome Research, Inc. | Compounds and compositions for treating conditions associated with nlrp activity |
| GB201819083D0 (en) | 2018-11-23 | 2019-01-09 | Inflazome Ltd | Novel compounds |
| US20220227707A1 (en) | 2019-01-22 | 2022-07-21 | Novartis Ag | Compounds and compositions for treating conditions associated with nlrp activity |
| EP3914585A1 (en) | 2019-01-23 | 2021-12-01 | Novartis AG | Sulfonimidamide compounds and compositions for treating conditions associated with nlrp activity |
| HUE060364T2 (hu) | 2019-03-29 | 2023-02-28 | Medimmune Ltd | Vegyületek és konjugátumaik |
| EP3986879B1 (en) | 2019-06-21 | 2024-10-02 | AC Immune SA | Fused 1,2-thiazoles and 1,2-thiazines which act as nlrp3 modulators |
| WO2021002887A1 (en) | 2019-07-02 | 2021-01-07 | Novartis Inflammasome Research, Inc. | Gut-targeted nlrp3 antagonists and their use in therapy |
| CA3165238A1 (en) | 2019-12-19 | 2021-06-24 | Jacobio Pharmaceuticals Co., Ltd. | Kras mutant protein inhibitors |
| PH12022551767A1 (en) | 2020-01-22 | 2023-11-29 | Hoffmann La Roche | Sulfonimidamide compounds as nlrp3 modulators |
| TWI785474B (zh) | 2020-01-22 | 2022-12-01 | 大陸商北京加科思新藥研發有限公司 | 用作選擇性Aurora A抑制劑的新型雜環化合物 |
| AR121078A1 (es) | 2020-01-22 | 2022-04-13 | Chugai Pharmaceutical Co Ltd | Derivados de arilamida con actividad antitumoral |
| CN115052852A (zh) | 2020-01-29 | 2022-09-13 | 巴利阿里群岛大学 | α-羟基化脂肪酸代谢产物、其医学用途以及作为生物标志物的用途 |
| EP4139312A1 (en) | 2020-04-23 | 2023-03-01 | JANSSEN Pharmaceutica NV | Tricyclic compounds as inhibitors of nlrp3 |
| MX2022013637A (es) | 2020-04-30 | 2022-11-16 | Janssen Pharmaceutica Nv | Nuevos compuestos de triazinoindol. |
| WO2021234608A1 (en) | 2020-05-19 | 2021-11-25 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US20230202989A1 (en) | 2020-05-28 | 2023-06-29 | Janssen Pharmaceutica Nv | Compounds |
| AU2021291065B2 (en) | 2020-06-19 | 2025-06-26 | Ac Immune Sa | Dihydrooxazole and thiourea or urea derivatives modulating the nlrp3 inflammasome pathway |
| IL277528B (en) | 2020-09-22 | 2022-05-01 | Ag Plenus Ltd | Herbicidal compounds and methods of their use |
| CN116194445A (zh) | 2020-09-24 | 2023-05-30 | 詹森药业有限公司 | 新化合物 |
| JP2024508017A (ja) | 2021-03-04 | 2024-02-21 | ヤンセン ファーマシューティカ エヌ．ベー． | Ｎｌｒｐ３を調節する４－アルコキシ－６－オキソ－ピリダジン誘導体 |
| AU2022263621A1 (en) | 2021-04-29 | 2023-12-14 | Janssen Pharmaceutica Nv | Phthalazinone derivatives as nlrp3 inflammasome inhibitors |
| CN116917282A (zh) | 2021-05-10 | 2023-10-20 | 成都百裕制药股份有限公司 | 酰胺衍生物及其应用 |
| KR20240029027A (ko) | 2021-07-01 | 2024-03-05 | 얀센 파마슈티카 엔브이 | 5-옥소-피리도[2,3-d]피리다진-6(5H)-일 아세트아미드 |
-
2019
- 2019-07-19 CA CA3105521A patent/CA3105521A1/en active Pending
- 2019-07-19 EP EP19753515.6A patent/EP3823974A1/en active Pending
- 2019-07-19 BR BR112021001044-0A patent/BR112021001044A2/pt unknown
- 2019-07-19 CN CN201980048375.6A patent/CN112513048A/zh active Pending
- 2019-07-19 JP JP2021502987A patent/JP7320595B2/ja active Active
- 2019-07-19 KR KR1020217002210A patent/KR20210034596A/ko not_active Withdrawn
- 2019-07-19 WO PCT/US2019/042711 patent/WO2020018975A1/en not_active Ceased
- 2019-07-19 MX MX2021000780A patent/MX2021000780A/es unknown
- 2019-07-19 PE PE2021000082A patent/PE20211811A1/es unknown
- 2019-07-19 CR CR20210022A patent/CR20210022A/es unknown
- 2019-07-19 SG SG11202013062VA patent/SG11202013062VA/en unknown
- 2019-07-19 MA MA053172A patent/MA53172A/fr unknown
- 2019-07-19 AU AU2019306658A patent/AU2019306658A1/en not_active Abandoned
- 2019-07-19 UA UAA202100695A patent/UA128558C2/uk unknown
- 2019-07-22 TW TW108125886A patent/TWI825134B/zh not_active IP Right Cessation
- 2019-07-22 AR ARP190102055A patent/AR115822A1/es not_active Application Discontinuation
-
2020
- 2020-12-07 IL IL279256A patent/IL279256A/en unknown
-
2021
- 2021-01-15 US US17/150,349 patent/US12234245B2/en active Active
- 2021-01-19 CL CL2021000153A patent/CL2021000153A1/es unknown
- 2021-01-19 PH PH12021500005A patent/PH12021500005A1/en unknown
- 2021-02-10 CO CONC2021/0001530A patent/CO2021001530A2/es unknown
-
2024
- 2024-12-19 US US18/988,433 patent/US20250115618A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210034596A (ko) | 2021-03-30 |
| AR115822A1 (es) | 2021-03-03 |
| SG11202013062VA (en) | 2021-02-25 |
| CR20210022A (es) | 2021-02-18 |
| JP7320595B2 (ja) | 2023-08-03 |
| TWI825134B (zh) | 2023-12-11 |
| EP3823974A1 (en) | 2021-05-26 |
| AU2019306658A1 (en) | 2021-01-07 |
| CN112513048A (zh) | 2021-03-16 |
| MA53172A (fr) | 2021-05-26 |
| PH12021500005A1 (en) | 2021-09-13 |
| WO2020018975A1 (en) | 2020-01-23 |
| US12234245B2 (en) | 2025-02-25 |
| US20210253596A1 (en) | 2021-08-19 |
| BR112021001044A2 (pt) | 2021-04-13 |
| US20250115618A1 (en) | 2025-04-10 |
| UA128558C2 (uk) | 2024-08-14 |
| CL2021000153A1 (es) | 2021-07-09 |
| IL279256A (en) | 2021-01-31 |
| MX2021000780A (es) | 2021-03-31 |
| TW202016078A (zh) | 2020-05-01 |
| CA3105521A1 (en) | 2020-01-23 |
| CO2021001530A2 (es) | 2021-03-08 |
| JP2021532101A (ja) | 2021-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20211811A1 (es) | Compuestos de sulfonimidamida como inhibidores de la actividad de interleucina-1 | |
| MX2022003166A (es) | Moduladores de il-17a y usos de los mismos. | |
| MX2022009309A (es) | Compuestos y usos de los mismos. | |
| CL2019001988A1 (es) | Compuestos químicos como inhibidores de actividad interleuquina-2. | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| ECSP21050201A (es) | Inhibidores de imidazo[1,2-b]piridazina il-17a | |
| CR20220200A (es) | Compuestos de heteroarilo bicíclicos y usos de estos | |
| CO2021016015A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
| CO2024011455A2 (es) | Moduladores de il-17a basados en diciclopropilo y usos de estos | |
| CO2020002961A2 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| MX2022007369A (es) | Compuestos de quinolinonilo piperazina sustituidos utiles como activadores de celulas t. | |
| CO2022016899A2 (es) | Moduladores de il-17a | |
| CR20120562A (es) | Compuestos heterocíclicos y sus usos | |
| CL2009000650A1 (es) | Compuestos derivados de amino-pirazina, inhibidores de cinasa-pi 3; composicion farmaceutica; y uso para el tratamiento de condiciones inflamatorias o alérgicas, tales como enfermedades respiratorias, artritis reumatoide, colitis ulcerativa, entre otras | |
| CL2021001656A1 (es) | Compuestos de imidazopiridina e imidazopiridina y sus usos. | |
| CR11582A (es) | Compuestos heterociclicos y sus usos | |
| CO2022018636A2 (es) | Moduladores de il-17a | |
| GT200800227A (es) | Antagonistas del receptor de vanilloides del subtipo (vr1) y usos de los mismos | |
| PE20170703A1 (es) | Moduladores de pirrolopiridina de rorc2 sustituidos con metilo y trifluorometilo y metodos de uso de los mismos | |
| CL2018000231A1 (es) | Análogos de adamantilureas como inhibidores de epoxido hidrolasa soluble | |
| CL2022001887A1 (es) | Pirazolo-pirimidinas sustituidas y usos de las mismas | |
| MX2016002738A (es) | Compuestos farmaceuticos. | |
| CL2023001195A1 (es) | Compuestos bicíclicos y usos de los mismos para el tratamiento de enfermedades. | |
| CO2022008313A2 (es) | Compuestos químicos |